Network-Based Systems Analysis Explains Sequence-Dependent Synergism of Bortezomib and Vorinostat in Multiple Myeloma
- 17 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (5), 1-12
- https://doi.org/10.1208/s12248-021-00622-9
Abstract
Bortezomib and vorinostat exhibit synergistic effects in multiple myeloma (MM) cells when given in sequence, and the purpose of this study was to evaluate the molecular determinants of the interaction using a systems pharmacology approach. A Boolean network model consisting of 79 proteins and 225 connections was developed using literature information characterizing mechanisms of drug action and intracellular signal transduction. Network visualization and structural analysis were conducted, and model simulations were compared with experimental data. Critical biomarkers, such as pNFκB, p53, cellular stress, and p21, were identified using measures of network centrality and model reduction. U266 cells were then exposed to bortezomib (3 nM) and vorinostat (2 μM) as single agents or in simultaneous and sequential (bortezomib for first 24 h, followed by addition of vorinostat for another 24 h) combinations. Temporal changes for nine of the critical proteins in the reduced Boolean model were measured over 48 h, and cellular proliferation was measured over 96 h. A mechanism-based systems model was developed that captured the biological basis of a bortezomib and vorinostat sequence-dependent pharmacodynamic interaction. The model was further extended in vivo by linking in vitro parameter values and dynamics of p21, caspase-3, and pAKT biomarkers to tumor growth in xenograft mice reported in the literature. Network-based methodologies and pharmacodynamic principles were integrated successfully to evaluate bortezomib and vorinostat interactions in a mechanistic and quantitative manner. The model can be potentially applied to evaluate their combination regimens and explore in vivo dosing regimens.Keywords
This publication has 58 references indexed in Scilit:
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Combinatorial Chemotherapeutic Efficacy in Non-Hodgkin Lymphoma Can Be Predicted by a Signaling Model of CD20 PharmacodynamicsCancer Research, 2012
- Disruption of IκB Kinase (IKK)-mediated RelA Serine 536 Phosphorylation Sensitizes Human Multiple Myeloma Cells to Histone Deacetylase (HDAC) InhibitorsOnline Journal of Public Health Informatics, 2011
- SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axisCell Death & Differentiation, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cellsBlood, 2009
- JNK signaling in apoptosisOncogene, 2008
- Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHABlood, 2008
- Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapyCancer Letters, 2008
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003